Study Background and Disease Burden
Atrial fibrillation (AF) frequently emerges as a complication following cardiac surgery, affecting a substantial proportion of patients and complicating postoperative management. New-onset AF is associated with increased risk of stroke, thromboembolic events, prolonged hospitalization, and higher healthcare costs. Traditionally, warfarin has been the anticoagulant cornerstone for stroke prevention in patients with AF, including post-surgical cases. However, direct oral anticoagulants (DOACs) such as rivaroxaban have gained prominence in non-surgical populations due to predictable pharmacokinetics, rapid onset of action, fewer monitoring requirements, and comparable efficacy and safety profiles compared to warfarin. Despite these advantages, DOACs have not been systematically evaluated in the postcardiac surgery population, leaving uncertainty about their role and benefits in this group. The NEW-AF trial addresses this knowledge gap by directly comparing rivaroxaban and warfarin in patients with new-onset AF after cardiac surgery to inform clinical decision-making.
